Blog - Page 2 of 5657 - QualityStocks

ThursdayJun 11, 2026 9:00 am

VERAXA Biotech AG (NASDAQ: VRXA) Is ‘One to Watch’

VERAXA is advancing a diversified oncology pipeline spanning monoclonal antibodies, antibody-drug conjugates, bispecific ADCs and proprietary BiTAC-based therapeutic formats across multiple cancer indications. The company’s proprietary BiTAC platform is designed to conditionally activate therapeutic activity at tumor sites, with the goal of improving target specificity while reducing off-tumor toxicity. Through its focus on ADCs and TCEs, VERAXA is positioned within two rapidly growing segments of the global oncology therapeutics market. Via selected partnerships, VERAXA aims to contribute value to developments in complementary therapeutic sectors such as radioimmunoconjugates (“RICs”) and antibody-oligonucleotide conjugates (“AOCs”). VERAXA Biotech has successfully concluded a business combination…

WednesdayJun 10, 2026 1:45 pm

QualityStocksNewsBreaks – Fairchild Gold (TSX-V: FAIR; OTCQB: FCHDF; Frankfurt: Y4Y) Shareholders Approve Golden Arrow Property Acquisition

This article has been disseminated on behalf of Fairchild Gold Corp. and may include paid advertising. Fairchild Gold (TSX-V: FAIR; OTCQB: FCHDF; Frankfurt: Y4Y) announced that shareholders approved the company's previously announced acquisition of the Golden Arrow Property from Emergent Metals Corp. at a special meeting held June 9, 2026. Shareholders representing 18.5 million common shares, or approximately 10.3% of the issued and outstanding shares eligible to vote, were represented at the meeting. Fairchild Gold said all eligible votes cast were in favor of the transaction. Completion of the acquisition remains subject to final regulatory approvals, including approval from the…

WednesdayJun 10, 2026 10:32 am

QualityStocksNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Completes First Psilocybin Export to United Kingdom for Planned Phase 2 Trial

This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising. Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) announced the completion of its first export of naturally derived psilocybin to the United Kingdom in support of a planned Phase 2 clinical trial. The shipment includes psilocybin biomass and finished 5 mg psilocybin capsules manufactured at the company's GMP facility in Princeton, British Columbia. Optimi Health said the capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression and were exported under authorization from Health Canada and the UK Home Office.…

WednesdayJun 10, 2026 9:50 am

QualityStocksNewsBreaks – ParaZero Technologies Ltd. (NASDAQ: PRZO) Secures New Orders for DefendAir Counter-UAS Systems in Israel

ParaZero Technologies (NASDAQ: PRZO) announced that it has secured two new purchase orders in Israel for its DefendAir Net Pods from separate companies developing autonomous counter-unmanned aerial systems solutions. The agreements support the integration of ParaZero's net-based drone interception technology into advanced sensor-driven and autonomous defense platforms. ParaZero Technologies said the orders follow the recent establishment of a new production line designed to expand manufacturing capacity for its DefendAir product ecosystem. The company noted that the deals reflect growing demand for integrated counter-drone architectures that combine detection, tracking and autonomous engagement capabilities with non-explosive physical interception technologies aimed at neutralizing…

WednesdayJun 10, 2026 9:30 am

QualityStocksNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Highlights Fiscal 2026 Growth and Cash Flow Progress in Shareholder Letter

Earth Science Tech (OTC: ETST) provided a business update in a letter to shareholders, highlighting what management described as a transformational fiscal year ended March 31, 2026. The company cited progress across multiple holdings, including the expansion of Mister Meds, turnarounds at DOConsultation and Villas Health, the relaunch of MyOnlineConsultation as a cash flow-positive prescriber network and revenue growth at Peaks that surpassed $2 million during the first week of the fourth quarter. Earth Science Tech said it completed these initiatives without adding debt to its balance sheet, while also repurchasing and retiring more than 3.7 million shares during the…

WednesdayJun 10, 2026 9:20 am

QualityStocksNewsBreaks – BOXABL and FG Merger II Corp. (NASDAQ: FGMC) Stockholders Approve Business Combination

BOXABL FG Merger II Corp. (NASDAQ: FGMC) announced that stockholders of both companies approved the previously announced business combination at their respective special meetings held June 9, 2026. Upon completion of the transaction, FGMC will be renamed BOXABL Inc., with the combined company's common stock expected to begin trading on the Nasdaq Stock Market under the ticker symbol BXBL. BOXABL said its stockholders approved the business combination proposal, while FGMC stockholders approved all proposals required to complete the transaction, including the business combination, governance, stock issuance and director election proposals. Company executives said the combination will provide BOXABL with access…

WednesdayJun 10, 2026 9:10 am

QualityStocksNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) Advances ONC010 Manufacturing Process Development

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) announced the initiation of process development and intermediate scale-up activities for A83B4C63, the active pharmaceutical ingredient in its proprietary drug candidate ONC010. The work represents a key milestone in the company's chemistry, manufacturing and controls strategy as it advances toward IND-enabling studies and planning for first-in-human clinical evaluation. Onco said the program will focus on optimizing synthetic processes, improving yield and reproducibility and scaling production of key intermediates required for downstream manufacturing and formulation. The…

WednesdayJun 10, 2026 9:00 am

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) Is ‘One to Watch’

Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising. Onco-Innovations is developing ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor designed to target DNA repair pathways involved in cancer survival and treatment resistance. The company is positioning itself as a leader in the emerging PNKP inhibitor class, a segment of the broader DNA Damage Response therapy market that is distinct from established PARP inhibitor therapies. Five patents protect the company’s PNKP inhibitor technology, nanoparticle delivery platform and related applications, supporting its intellectual property position as development advances. Through its wholly owned subsidiary Inka Health, Onco-Innovations has…

WednesdayJun 10, 2026 9:00 am

QualityStocksNewsBreaks – Rising Fuel Costs Threaten Consumer Spending as Retailers Brace for Slower Growth

Berkshire Hathaway Inc. (NYSE: BRK.A) (NYSE: BRK.B) and other investors with significant exposure to the retail sector may be closely watching consumer spending trends after Walmart warned that rising gasoline prices are putting increasing pressure on household budgets. The retailer expects sales growth to slow in the current quarter as higher fuel costs, driven in part by geopolitical tensions and disruptions to global energy markets, force consumers to allocate more of their income to essential expenses. Walmart also cautioned that ongoing supply-chain challenges could lead to higher food prices if shipping disruptions persist, adding further strain on consumers. Despite reporting strong…

TuesdayJun 09, 2026 11:40 am

QualityStocksNewsBreaks – SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) (Frankfurt: 5OV0) Achieves 43-Kilometer Maritime Target Acquisition Test

This article has been disseminated on behalf of SPARC AI Inc. and may include paid advertising. SPARC AI (CSE: SPAI) (OTCQB: SPAIF) (Frankfurt: 5OV0) announced the successful completion of a 43-kilometer long-range target acquisition test over open water in Port Phillip Bay, Australia, using its Overwatch GPS-denied navigation and targeting platform. The company said the demonstrated range is comparable to, and in some measurements exceeds, the narrowest width of the Strait of Hormuz, highlighting the platform's potential applicability in contested maritime environments. SPARC AI also announced the integration of image recognition capabilities into its drone controller application, enabling operators to…

Site Search

Company Search